Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
RO7105705 MTAU9937A,
RG6100
Alzheimer's Disease (Phase 2) AC Immune SA, Genentech, Hoffmann-La Roche Tau Immunotherapy (passive)
Zagotenemab LY3303560 Alzheimer's Disease (Phase 2) Eli Lilly & Co. Tau, Unknown Immunotherapy (passive)
AADvac-1 Axon peptide 108 conjugated to KLH Alzheimer's Disease (Phase 2), Progressive Nonfluent Aphasia (Phase 1) Axon Neuroscience SE Tau Immunotherapy (active)
BIIB092 gosuranemab,
BMS-986168, IPN007
Progressive Supranuclear Palsy (Phase 2), Alzheimer's Disease (Phase 2) Biogen, Bristol-Myers Squibb Tau Immunotherapy (passive)
C2N 8E12 ABBV-8E12 Progressive Supranuclear Palsy (Phase 2), Alzheimer's Disease (Phase 2) AbbVie, C2N Diagnostics, LLC Tau Immunotherapy (passive)